Latest Breaking News On - Carl pepine - Page 1 : comparemela.com

BioCardia s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

BioCardia s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

United statesCarl pepinePeter altmanUniversity of wisconsin at madisonBiocardia incUniversity florida at gainesvilleCardiamp cell therapy programSteering committeeChronic myocardial ischemiaExecutive steering committeeUniversity floridaAmish ravalBreakthrough therapyIschemic heart failure

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

United statesPeter altmanDebby holmes higginCarl pepineDavid andersonUniversity of florida at gainesvilleBiocardia incYork heart association classCatheterization labNational principal investigatorDivision of cardiovascular medicineNew york heart association classCardiovascular medicineInterventional cardiologyCardiac catheterization labVice president

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavid mcclungDebby holmes higginPeter altmanCarl pepineMiranda petoDavid andersonYork heart association classBiocardia incUniversity of florida at gainesvilleDivision of cardiovascular medicineNational principal investigatorCatheterization labExchange commission onAllogeneic mesenchymal cell therapy phaseNew york heart association class

BioCardia, Inc : BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc : BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStefan klotterDebby holmes higginDavid andersonCarl pepinePeter altmanBiocardia incCatheterization labDivision of cardiovascular medicineUniversity of florida at gainesvilleExchange commission onYork heart association classNational principal investigatorNew york heart association classCardiovascular medicineInterventional cardiology

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP® Cell Therapy for Heart Failure (CardiAMP HF, clinicaltrials.gov Identifier: NCT02438306), for which the FDA granted Breakthrough Designation fo

United statesUniversity of wisconsinPeter altmanCarl pepineMiranda petoDavid mcclungStatistical data analysis centerExchange commission onUniversity of florida at gainesvilleNational principal investigatorBiocardia incNational principal investigatorsMaryland stem cell research fundCardiamp cell therapy programCell therapyHeart failure